- Ohtani eyes MLB history after surpassing 50 stolen bases, 49 homers
- Ohtani eyes MLB history after surpassing 50 stolen bases
- Barca downed by Monaco as Arsenal held in Champions League stalemate
- Head's 'good night at office' after century seals win over England
- Dubois seeks legitimacy with Joshua scalp
- Rate cut could lift consumer spirits before US elections
- Last-gasp Gimenez strike sends Atletico past Leipzig
- Barca stumble at Monaco after early red card
- Raya heroics save Arsenal in Champions League opener at Atalanta
- Cathay Airbus engine fire linked to cleaning: EU regulator
- Guardians beat Twins to secure MLB playoff berth
- Jihadist attack in Mali capital killed more than 70: security sources
- Alonso hails 'efficient' Leverkusen after Feyenoord rout
- Head's hundred seals Australia win over England in 1st ODI
- Ex-Man United striker Anthony Martial joins AEK Athens
- NFL unbeatens meet as Texans visit Vikings, Steelers host Chargers
- Head's hundred seals Australia win over England in 1st ODI after Labuschagne strikes
- Dream debut for Wirtz as Leverkusen thump dire Feyenoord
- Myanmar flood death toll climbs to 293: state media
- Israel army says West Bank air strike kills 4 militants
- LIV golfers get green light for US Ryder Cup team, PGA Championship
- US accuses social media giants of 'vast surveillance'
- Ten Hag to bed Hojlund, Mount in carefully when they return for Man Utd
- Breaking bad as McIlroy endures 'weird' day
- EU chief announces $11 bn for nations hit by 'heartbreaking' floods
- Spanish PM, Palestinian leader urge Mideast de-escalation
- New study reinforces theory Covid emerged at Chinese market
- World Bank boosts climate financing by 10 percent
- Bagnaia eyeing summit on home ground in 100th MotoGP
- 'Something was wrong', defendant in French mass rape tells court
- Hezbollah chief admits 'unprecedented' blow in device blasts
- Sales of US existing homes slip slightly in August
- Fear, panic haunt Lebanese after devices explode
- Labuschagne sparks Australia fightback in England ODI opener
- S.Africa's HIV research power couple says fight goes on
- Why is Israel focusing on border with Lebanon?
- Mpox vaccines administered in Rwanda, first in Africa
- US Fed rate cut is 'very positive sign' for economy: Yellen
- Unknown Mozart string trio discovered in Germany
- 'Are we five-year-olds?' F1 drivers won't mind their language
- Brazil judge orders X to reimpose block or face hefty fine
- Munich to rename stadium street after Beckenbauer
- Champions Italy to face Argentina in Davis Cup Final 8
- The winding, fitful path to weight loss drug Ozempic
- Italians defeat American Magic to reach Louis Vuitton Cup final
- Norris has 'nothing to lose' as he hunts Verstappen in Singapore
- Kyiv 'outraged' at Swiss showing of Russian war film
- French city renames Abbe Pierre square after abuse claims
- Footballer charged after huge cannabis seizure at UK airport
- Vatican recognises Medjugorje shrine, but not Virgin's messages
US panel recommends Covid vaccines for youngest children
A panel of experts convened by the US Food and Drug Administration unanimously recommended Covid-19 vaccines Wednesday for children under five, the final age group awaiting immunization in most countries.
Formal authorizations should follow soon, with the first shots in arms expected early next week, just over a year-and-a-half after the first Covid vaccines were greenlighted for the elderly in December 2020.
"This recommendation does fill a significant unmet need for a really ignored younger population," said Michael Nelson, a professor of medicine at the University of Virginia, one of the 21 experts asked to vote for the milestone meeting.
Unlike regulators in other countries, FDA offers livestreams of its internal deliberations and its stamp of approval is considered the global gold standard.
Opening the discussion, senior FDA scientist Peter Marks said that despite studies showing the majority of children have now been infected with the coronavirus, the high rate of hospitalizations among infants, toddlers and young children during last winter's Omicron wave underscored an urgent need for vaccination.
"We are dealing with an issue where we have to be careful we don't become numb to the pediatric deaths because of the overwhelming number of older deaths," he said.
"Every life is important and vaccine-preventable deaths are something we would like to try to do something about."
The United States has recorded 480 Covid deaths in the 0-4 age group in the pandemic -- far higher than even a bad flu season, Marks said.
As of May 2022, there have been 45,000 hospitalizations in that group, nearly a quarter of which required intensive care.
Ahead of the meeting, the FDA posted its independent analyses of the pharmaceutical companies' vaccines, deeming both safe and effective.
Both vaccines are based on messenger RNA, which delivers genetic code for the coronavirus spike protein to human cells that then grow it on their surface, training the immune system to be ready. The technology is now considered the leading Covid vaccination platform.
Pfizer sought authorization for three doses at three micrograms given to children aged six months through four years, while Moderna asked for the FDA to authorize its vaccine as two doses of a higher 25 micrograms for ages six months through five years.
Both vaccines were tested in trials of thousands of children. They were found to cause similar levels of mild side effects as in older age groups and triggered similar levels of antibodies.
- Two doses, or three? -
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent, compared to Moderna's estimates of 51 percent for children aged six-months to two years old and 37 percent for those aged two to five years.
But the Pfizer figure is based on very few cases and is thus considered preliminary. It also takes three doses to achieve its protection, with the third shot given eight weeks after the second, which is given three weeks after the first.
Moderna's vaccine should provide strong protection against severe disease after two doses, given four weeks apart, and the company is studying adding a booster that would raise efficacy levels against mild disease.
However, Moderna's decision to go with a higher dose is associated with higher levels of fevers in reaction to the vaccine compared to Pfizer.
There are some 20 million US children aged four years and under.
Although obesity, neurological disorders and asthma are associated with increased risk of severe disease among young children, it's not easy to predict severe outcomes.
In fact, 64 percent of hospitalizations in those under five occurred in patients without comorbidities.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition. Some three to six percent can experience long Covid symptoms for more than 12 weeks.
The FDA is expected to soon act on the panel's recommendation, and the matter will go to the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of 10 million shots at pharmacies and doctors' offices could begin as soon as June 21.
J.Williams--AMWN